NCT00314132View on ClinicalTrials.gov

Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.

PHASE3CompletedINTERVENTIONAL
Enrollment

2,004

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

November 30, 2006

Study Completion Date

November 30, 2006

Conditions
EncephalitisJapanese Encephalitis
Interventions
BIOLOGICAL

ChimeriVax-JE, Japanese Encephalitis vaccine

0.5 mL, Subcutaneous

BIOLOGICAL

0.9% Saline

0.5 mL, Subcutaneous

Trial Locations (22)

27109

Winston-Salem

32809

Orlando

33024

Pembroke Pines

33173

Miami

40004

Bardstown

48152

Livonia

52242

Iowa City

65802

Sprnigfield

66212

Overland Park

68134

Omaha

76135

Fort Worth

92505

Burbank

92708

Costa Mesa

94102

San Francisco

94589

Vallejo

95616

Davis

NSW 2010

Darlinghurst

QLD 4051

Enoggera

VIC 3081

Heidelbeg West

QLD 4021

Kippa-Ring

VIC 3082

Mill Park

SA 5056

Toorak Gardens

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY